Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy : a nationwide Danish cohort study. / Madsen, Christoffer Valdorff; Bundgaard, Henning; Rasmussen, Åse Krogh; Sørensen, Søren Schwartz; Petersen, Jørgen Holm; Køber, Lars; Feldt-Rasmussen, Ulla; Petri, Helle.
In: Scandinavian Cardiovascular Journal, Vol. 51, No. 4, 2017, p. 207-216.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy
T2 - a nationwide Danish cohort study
AU - Madsen, Christoffer Valdorff
AU - Bundgaard, Henning
AU - Rasmussen, Åse Krogh
AU - Sørensen, Søren Schwartz
AU - Petersen, Jørgen Holm
AU - Køber, Lars
AU - Feldt-Rasmussen, Ulla
AU - Petri, Helle
PY - 2017
Y1 - 2017
N2 - OBJECTIVES: In patients with Fabry disease (FD), left ventricular hypertrophy and arrhythmias are frequently observed and cardiac involvement is the leading cause of death. Long-term efficacy of enzyme replacement therapy (ERT) on cardiac involvement is unclear. We assessed and compared long-term progression of cardiac involvement according to ERT and non-ERT.METHODS: We retrospectively assessed and compared long-term progression of cardiac involvement in adult patients with FD in the nationwide Danish cohort. We followed clinical signs, symptoms and findings by echocardiography, electrocardiography and Holter-monitoring.RESULTS: We included 66 patients; 47 patients (27 women) received ERT (ERT group) and 19 patients (15 women) did not (non-ERT group). The groups were followed for a median of 8 [0-12] years and 6 [0-13] years, respectively. Comparison between ERT and non-ERT receiving patients by left ventricular mass (echocardiographic assessment) and Sokolow-Lyon voltage- and Cornell product criteria (electrocardiographic assessment) revealed no significant differences. In the ERT group, we observed no change in left ventricular mass but a decrease in Sokolow-Lyon voltage- and Cornell product criteria from baseline to follow-up; 30 mm [15-53] vs. 25 mm [3-44], p < 0.005 and 1710 mm·ms [480-3740] vs. 1520 mm·ms [550-5740], p < .05, respectively. There were no changes within the non-ERT group. During follow-up, cardiac symptoms and use of cardiovascular procedures and -medication increased significantly in the ERT group, whereas no differences were observed within the non-ERT group.DISCUSSION: We raise concerns regarding the efficacy and benefit of ERT on cardiac involvement in Fabry disease and stress the need for further research.
AB - OBJECTIVES: In patients with Fabry disease (FD), left ventricular hypertrophy and arrhythmias are frequently observed and cardiac involvement is the leading cause of death. Long-term efficacy of enzyme replacement therapy (ERT) on cardiac involvement is unclear. We assessed and compared long-term progression of cardiac involvement according to ERT and non-ERT.METHODS: We retrospectively assessed and compared long-term progression of cardiac involvement in adult patients with FD in the nationwide Danish cohort. We followed clinical signs, symptoms and findings by echocardiography, electrocardiography and Holter-monitoring.RESULTS: We included 66 patients; 47 patients (27 women) received ERT (ERT group) and 19 patients (15 women) did not (non-ERT group). The groups were followed for a median of 8 [0-12] years and 6 [0-13] years, respectively. Comparison between ERT and non-ERT receiving patients by left ventricular mass (echocardiographic assessment) and Sokolow-Lyon voltage- and Cornell product criteria (electrocardiographic assessment) revealed no significant differences. In the ERT group, we observed no change in left ventricular mass but a decrease in Sokolow-Lyon voltage- and Cornell product criteria from baseline to follow-up; 30 mm [15-53] vs. 25 mm [3-44], p < 0.005 and 1710 mm·ms [480-3740] vs. 1520 mm·ms [550-5740], p < .05, respectively. There were no changes within the non-ERT group. During follow-up, cardiac symptoms and use of cardiovascular procedures and -medication increased significantly in the ERT group, whereas no differences were observed within the non-ERT group.DISCUSSION: We raise concerns regarding the efficacy and benefit of ERT on cardiac involvement in Fabry disease and stress the need for further research.
KW - Adolescent
KW - Adult
KW - Aged
KW - Arrhythmias, Cardiac
KW - Denmark
KW - Disease Progression
KW - Echocardiography
KW - Electrocardiography, Ambulatory
KW - Enzyme Replacement Therapy
KW - Fabry Disease
KW - Female
KW - Humans
KW - Hypertrophy, Left Ventricular
KW - Isoenzymes
KW - Male
KW - Middle Aged
KW - Predictive Value of Tests
KW - Retrospective Studies
KW - Time Factors
KW - Treatment Outcome
KW - Young Adult
KW - alpha-Galactosidase
KW - Comparative Study
KW - Journal Article
U2 - 10.1080/14017431.2017.1332383
DO - 10.1080/14017431.2017.1332383
M3 - Journal article
C2 - 28545342
VL - 51
SP - 207
EP - 216
JO - Scandinavian Cardiovascular Journal
JF - Scandinavian Cardiovascular Journal
SN - 1401-7458
IS - 4
ER -
ID: 186643700